<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" bill-type="olc" dms-id="A1" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S1364 IS: Medicaid Generic Drug Price Fairness Act of 2015</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-05-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>114th CONGRESS</congress><session>1st Session</session><legis-num>S. 1364</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20150518">May 18, 2015</action-date><action-desc><sponsor name-id="S313">Mr. Sanders</sponsor> (for himself, <cosponsor name-id="S307">Mr. Brown</cosponsor>, <cosponsor name-id="S361">Ms. Hirono</cosponsor>, <cosponsor name-id="S341">Mr. Blumenthal</cosponsor>, and <cosponsor name-id="S332">Mr. Franken</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend title XIX of the Social Security Act to require the payment of an additional rebate to the
			 State Medicaid plan in the case of increase in the price of a generic drug
			 at a rate that is greater than the rate of inflation. </official-title></form>
	<legis-body id="H300F91C7F0AE427C9A006A594CBACBAD" style="OLC">
 <section id="H0B0840E3EF9E4447933582E4CC04B22E" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medicaid Generic Drug Price Fairness Act of 2015</short-title></quote>.</text> </section><section id="HEB695578114349CB84779B3BFDDCA362"><enum>2.</enum><header>Applying the medicaid additional rebate requirement to generic drugs</header> <subsection id="H48972611F47B41E2A294E5BEDB40D090"><enum>(a)</enum><header>In general</header><text>Section 1927(c)(3) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(c)(3)</external-xref>) is amended—</text>
 <paragraph id="H3A98BBECEDE642C39837391067815E22"><enum>(1)</enum><text>in subparagraph (A), by striking <quote>The amount</quote> and inserting <quote>Except as provided in subparagraph (C), the amount</quote>; and</text> </paragraph><paragraph id="H9A97DDED1C67435382CE2233C0C53D7A"><enum>(2)</enum><text>by adding at the end the following new subparagraph:</text>
					<quoted-block display-inline="no-display-inline" id="H36F833E2DE5947F8B96EDF0D59BDE550" style="OLC">
						<subparagraph id="H16342ED678FB424BA8970C3F5ECB6F73"><enum>(C)</enum><header>Additional rebate</header>
 <clause id="HEA2ADA099C704613A9D5273BE2480E84"><enum>(i)</enum><header>In general</header><text>The amount of the rebate specified in this paragraph for a rebate period, with respect to each dosage form and strength of a covered outpatient drug other than a single source drug or an innovator multiple source drug, shall be increased in the manner that the rebate for a dosage form and strength of a single source drug or an innovator multiple source drug is increased under subparagraphs (A) and (D) of paragraph (2), except as provided in clause (ii).</text>
 </clause><clause id="H0AAAB6BBEC53473AA0ED8B00C758B80B"><enum>(ii)</enum><header>Special rules for application of provision</header><text>In applying subparagraphs (A) and (D) of paragraph (2) under clause (i)—</text> <subclause id="HE7BF17E344BB4A4AB3CD744840CB2590"><enum>(I)</enum><text display-inline="yes-display-inline">the reference in subparagraph (A)(i) of such paragraph to <quote>1990</quote> shall be deemed a reference to <quote>2014</quote>;</text>
 </subclause><subclause id="H0CB1F8C692D541C8B58AD641749552B9"><enum>(II)</enum><text display-inline="yes-display-inline">subject to clause (iii), the reference in subparagraph (A)(ii) of such paragraph to <quote>calendar quarter beginning July 1, 1990</quote> shall be deemed a reference to the <quote>calendar quarter in which the average manufacturer price for the drug is the lowest during the 12-calendar quarter period ending on September 30, 2014</quote>; and</text>
 </subclause><subclause id="HEDA52A8FF1AC4EA5B907147F9965E73E"><enum>(III)</enum><text display-inline="yes-display-inline">subject to clause (iii), the reference in subparagraph (A)(ii) of such paragraph to <quote>September 1990</quote> shall be deemed a reference to <quote>the last month of such calendar quarter</quote>;</text> </subclause><subclause id="H8587C9677CD5461D9D6584BCC4074652"><enum>(IV)</enum><text display-inline="yes-display-inline">the references in subparagraph (D) of such paragraph to <quote>paragraph (1)(A)(ii)</quote>, <quote>this paragraph</quote>, and <quote>December 31, 2009</quote> shall be deemed references to <quote>subparagraph (A)</quote>, <quote>this subparagraph</quote>, and <quote>December 31, 2014</quote>, respectively; and</text>
 </subclause><subclause id="H597AF7B25D04493EB7DF2E33DABABB3A"><enum>(V)</enum><text>any reference in such paragraph to a <quote>single source drug or an innovator multiple source drug</quote> shall be deemed to be a reference to a drug to which clause (i) applies.</text> </subclause></clause><clause id="H037237BD844144BAA4501532BB8B21DC"><enum>(iii)</enum><header>Special rule for certain noninnovator multiple source drugs</header><text display-inline="yes-display-inline">In applying paragraph (2)(A)(ii)(II) under clause (i) with respect to a covered outpatient drug that is first sold as a drug other than a single source drug or an innovator multiple source drug after the date that is 3 years before the date of the enactment of this subparagraph, such paragraph shall be applied—</text>
 <subclause id="HEA5AD541DC9149FCB9A500AE041DBC09"><enum>(I)</enum><text>by substituting <quote>the applicable quarter</quote> for <quote>the calendar quarter beginning July 1, 1990</quote>; and</text> </subclause><subclause id="H460B26EAB5ED4098A77ABD6CB412B623"><enum>(II)</enum><text>by substituting <quote>the last month in such applicable quarter</quote> for <quote>September 1990</quote>.</text>
 </subclause></clause><clause id="H5366F4D1662946F9BB20E7F254FEE6DE"><enum>(iv)</enum><header>Applicable quarter defined</header><text display-inline="yes-display-inline">In this subsection, the term <term>applicable quarter</term> means, with respect to a drug described in clause (iii), the fifth full calendar quarter in which the drug is sold as a drug other than a single source drug or an innovator multiple source drug.</text>
							</clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H62C9B7F9A7754F7281562E6653B0D1AC"><enum>(b)</enum><header>Effective date</header><text>The amendments made by subsection (a) shall apply to rebate periods beginning after December 31, 2014.</text></subsection></section></legis-body></bill>


